• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.

作者信息

Espay Alberto J, Lang Anthony E

机构信息

UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio.

Morton and Gloria Shulman Movement Disorders Center, Toronto Western Hospital and The Edmond J. Safra Program in PD, Toronto, Ontario, Canada3University of Toronto, Toronto, Ontario, Canada.

出版信息

JAMA Neurol. 2017 Jun 1;74(6):633-634. doi: 10.1001/jamaneurol.2017.0348.

DOI:10.1001/jamaneurol.2017.0348
PMID:28459962
Abstract
摘要

相似文献

1
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.帕金森病左旋多巴使用中的常见误区：临床试验误导临床实践之时。
JAMA Neurol. 2017 Jun 1;74(6):633-634. doi: 10.1001/jamaneurol.2017.0348.
2
Agonists versus levodopa in PD: the thrilla of whitha.帕金森病中激动剂与左旋多巴的比较：一场激烈的较量
Neurology. 2003 Nov 25;61(10):1462; author reply 1462-3. doi: 10.1212/wnl.61.10.1462.
3
Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.左旋多巴诱发的运动障碍与阿扑吗啡持续皮下输注：一项为期两年的前瞻性随访结果
Mov Disord. 2002 Jan;17(1):188-91. doi: 10.1002/mds.1276.
4
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.多巴胺激动剂早期单一疗法用于延缓左旋多巴诱导的运动障碍的发生。
Expert Rev Neurother. 2015 Feb;15(2):207-13. doi: 10.1586/14737175.2015.1001747. Epub 2015 Jan 12.
5
Off spells and dyskinesias: pharmacologic management of motor complications.发作和运动障碍：运动并发症的药物治疗管理。
Cleve Clin J Med. 2012 Jul;79 Suppl 2:S8-13. doi: 10.3949/ccjm.79.s2a.02.
6
Thirty five years of experience in the treatment of Parkinson's disease with levodopa and associations.35年使用左旋多巴及联合用药治疗帕金森病的经验。
J Neural Transm Suppl. 2006(70):427-31. doi: 10.1007/978-3-211-45295-0_64.
7
Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.对多巴胺系统进行成像以评估疾病修饰药物：比较多巴胺激动剂和左旋多巴的研究。
Neurology. 2003 Sep 23;61(6 Suppl 3):S43-8. doi: 10.1212/wnl.61.6_suppl_3.s43.
8
[The role of dopaminagonists in the treatment of Parkinson's disease].[多巴胺激动剂在帕金森病治疗中的作用]
Praxis (Bern 1994). 2005 Oct 19;94(42):1633-8. doi: 10.1024/0369-8394.94.42.1633.
9
[Parkinson disease].[帕金森病]
Praxis (Bern 1994). 2001 Jun 7;90(23):1041-6.
10
Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).帕金森病中与运动波动和异动症相关的因素：新型美左旋多巴加卡比多巴制剂（Sirio）的潜在作用
Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924.

引用本文的文献

1
Use of safinamide for treatment of Parkinson disease: real-world data from Spain.沙芬酰胺用于治疗帕金森病：来自西班牙的真实世界数据。
Drugs Context. 2025 Jul 25;14. doi: 10.7573/dic.2025-5-5. eCollection 2025.
2
Pharmacotherapy for Disease Modification in Early Parkinson's Disease: How Early Should We Be?早期帕金森病的疾病修饰治疗：我们应该多早开始？
J Parkinsons Dis. 2024;14(s2):S407-S421. doi: 10.3233/JPD-230354.
3
Feasibility and effect of high-intensity training on the progression of motor symptoms in adult individuals with Parkinson's disease: A systematic review and meta-analysis.
高强度训练对成年帕金森病患者运动症状进展的可行性和效果：系统评价和荟萃分析。
PLoS One. 2023 Nov 10;18(11):e0293357. doi: 10.1371/journal.pone.0293357. eCollection 2023.
4
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.在托莱多运动障碍科，沙芬酰胺的疗效和安全性。
Rev Neurol. 2023 Oct 31;77(S03):S1-S7. doi: 10.33588/rn.77S03.2023212.
5
Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty.在晚期帕金森病中获得器械辅助治疗：应对临床医生偏见、患者偏好和预后不确定性。
J Neural Transm (Vienna). 2023 Nov;130(11):1411-1432. doi: 10.1007/s00702-023-02668-9. Epub 2023 Jul 12.
6
Parkinson disease primer, part 2: management of motor and nonmotor symptoms.帕金森病入门（二）：运动和非运动症状的管理。
Can Fam Physician. 2023 Feb;69(2):91-96. doi: 10.46747/cfp.690291.
7
Challenges in Parkinson's Disease Care-In Light of the COVID-19 Pandemic.帕金森病护理中的挑战——鉴于新冠疫情
J Mov Disord. 2023 Jan;16(1):52-54. doi: 10.14802/jmd.22085. Epub 2022 Nov 10.
8
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.帕金森病的精准医学：从遗传风险信号到个性化治疗
Brain Sci. 2022 Sep 28;12(10):1308. doi: 10.3390/brainsci12101308.
9
Deep Brain Stimulation in the Treatment of Parkinson's Disease.深部脑刺激治疗帕金森病
Cureus. 2022 Sep 3;14(9):e28760. doi: 10.7759/cureus.28760. eCollection 2022 Sep.
10
Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i.夏威夷农村和城市地区帕金森病医疗保险处方模式的差异。
Clin Park Relat Disord. 2022 Apr 22;6:100144. doi: 10.1016/j.prdoa.2022.100144. eCollection 2022.